文献速递垂体与肾上腺疾病

垂体腺瘤的胚系遗传景观:已知与新兴易感基因

The germline landscape of pituitary adenomas: established and emerging predisposition genes.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文综述垂体腺瘤胚系遗传易感性的已知基因(MEN1、PRKAR1A、AIP、CDKN1B、GPR101、SDHx、MAX)与新兴候选基因(CABLES1、CDH23、PAM、CHEK2、错配修复基因),强调对年轻发病、家族聚集或综合征特征患者进行胚系基因检测可指导个体化监测、预后判断、级联检测和生育规划。

要点

  • 已知胚系易感基因影响腺瘤表型、发病年龄、监测策略和家系筛查。
  • 新兴候选基因的致病性与临床相关性尚待完全确立。
  • 识别致病性胚系变异可支持基因特异性监测、预后判断、级联检测和生育规划。

核心结论

  • 垂体腺瘤部分患者存在胚系遗传成分,尤其年轻发病、家族聚集或综合征特征者。
  • 已知胚系易感基因在特定临床情境中影响腺瘤表型、发病年龄、监测策略和家系筛查。
  • 识别致病性胚系变异可支持个体化护理,包括基因特异性监测、预后判断、级联检测和生育规划。

研究设计与样本

  • 本文为临床导向的叙述性综述,总结垂体腺瘤胚系易感性的已知与新兴基因,并提出当代胚系基因检测的临床方法。

主要发现

  • 已知胚系易感基因包括MEN1、PRKAR1A、AIP、CDKN1B、GPR101、SDHx和MAX。
  • 新兴候选基因包括CABLES1、CDH23、PAM、CHEK2和错配修复基因,但其致病性与临床相关性尚待完全确立。

关键数值与推荐

  • 对年轻发病、家族聚集或综合征特征的垂体腺瘤患者应考虑胚系遗传评估。

临床怎么用

  • 对具有年轻发病、家族聚集或综合征特征的垂体腺瘤患者,应评估胚系遗传检测。
  • 检出致病性胚系变异后,可实施基因特异性监测、预后判断、家系级联检测和生育规划。

局限性

  • 新兴候选基因的致病性与临床相关性尚未完全确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pituitary adenomas are increasingly recognized to have a germline genetic component in a subset of patients, particularly those with young-onset disease, familial clustering or syndromic features. The spectrum of germline variants implicated in pituitary tumorigenesis has broadened considerably, with evidence of both established predisposition genes and a growing number of emerging candidate genes. Established germline predisposition genes-namely, MEN1, PRKAR1A, AIP, CDKN1B, GPR101, SDHx, and MAX-remain central to our understanding of familial pituitary adenoma predisposition and have defined roles in specific clinical contexts which influence adenoma phenotype, age at presentation, surveillance strategies, and family screening. Beyond this, a set of less prevalent variants in other genes-for example, CABLES1, CDH23, PAM, CHEK2, and the mismatch repair genes-are emerging as potential contributors, although the pathogenicity and clinical relevance of these genes remain to be fully established. Identifying causative germline variants in people with pituitary adenomas offers the opportunity of personalized care via gene-specific surveillance strategies, prognostication, cascade testing, and reproductive planning to the potential benefit of the individual as well as their families. In this review, we provide a clinically orientated overview of the established and emerging genes implicated in the germline predisposition to pituitary adenomas. We also present a contemporary clinical approach to germline genetic testing in patients with pituitary adenomas.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Mignone E, Sorvina A, Torpy DJ, et al. The germline landscape of pituitary adenomas: established and emerging predisposition genes. J Clin Endocrinol Metab. 2026. PMID: 42141904. doi:10.1210/clinem/dgag195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。